Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  EXACT Sciences Corporation    EXAS

EXACT SCIENCES CORPORATION

(EXAS)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/18/2019 03/19/2019 03/20/2019 03/21/2019 03/22/2019 Date
91.97(c) 91.15(c) 90.48(c) 92.02(c) 89(c) Last
2 578 931 1 385 083 1 740 503 1 897 764 1 786 510 Volume
-3.39% -0.89% -0.74% +1.70% -3.28% Change
More quotes
Financials (USD)
Sales 2019 729 M
EBIT 2019 -231 M
Net income 2019 -251 M
Finance 2019 132 M
Yield 2019 -
Sales 2020 1 057 M
EBIT 2020 -107 M
Net income 2020 -126 M
Finance 2020 109 M
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales2019 15,2x
EV / Sales2020 10,5x
Capitalization 11 193 M
More Financials
Company
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based... 
More about the company
Surperformance© ratings of EXACT Sciences Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on EXACT SCIENCES CORPORATION
03/19EXACT SCIENCES : Kathleen Sebelius Appointed to Exact Sciences Board
PU
03/04EXACT SCIENCES CORP : Change in Directors or Principal Officers (form 8-K)
AQ
02/21EXACT SCIENCES : 4Q Earnings Snapshot
AQ
02/21EXACT SCIENCES : Management's Discussion and Analysis of Financial Condition and..
AQ
02/05EXACT SCIENCES : schedules fourth-quarter, full-year 2018 earnings call
PU
01/06EXACT SCIENCES : to report $454-455M in total revenue, 71-percent growth for 201..
PU
2018EXACT SCIENCES CORP : Change in Directors or Principal Officers (form 8-K)
AQ
2018EXACT SCIENCES : to participate in J.P. Morgan Healthcare Conference
PU
2018EXACT SCIENCES : Israeli experts aim to ease parking squeeze with premium pricin..
AQ
2018EXACT SCIENCES : Madison companies dominate Deloitte Fast 500 technology firms
AQ
More news
Analyst Recommendations on EXACT SCIENCES CORPORATION
More recommendations
Sector news : Biotechnology & Medical Research - NEC
03/11Regeneron Says FDA Approves Dupixent for Atopic Dermatitis in Adolescents
DJ
03/08Regeneron, Sanofi Get FDA Priority Review for Dupixent
DJ
03/07SHANGHAI RAAS BLOOD PRODUCTS : Spain's Grifols, China's Shanghai RAAS form strat..
RE
03/06GILEAD SCIENCES : Says Once-Daily HIV Regimen Shows Promise in Treating Teens an..
DJ
03/05FDA Approves Controversial Drug for Depression -- Update
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart EXACT SCIENCES CORPORATION
Duration : Period :
EXACT Sciences Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXACT SCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 104 $
Spread / Average Target 17%
EPS Revisions
Managers
NameTitle
Kevin T. Conroy Chairman, President & Chief Executive Officer
Jeffrey T. Elliott Chief Financial Officer
Barry M. Berger Co-Chief Medical Officer & Head-Medical Affairs
Graham Peter Lidgard Chief Science Officer, SVP-Research & Development
Gary Frings Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
EXACT SCIENCES CORPORATION41.05%11 193
IQVIA HOLDINGS INC24.18%28 535
CELLTRION, INC.--.--%22 704
LONZA GROUP16.69%22 291
INCYTE CORPORATION34.20%18 639
SEATTLE GENETICS, INC.30.59%12 092